Bernstein Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $921

Benzinga Newsdesk www.benzinga.com Negative 93.9%

Neg 93.9% Neu 0% Pos 0%

Bernstein analyst William Pickering maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and lowers the price target from $925 to $921.